Filtered By:
Education: Study
Management: Healthcare Costs
This page shows you your search results in order of relevance. This is page number 12.
Order by Relevance | Date
Total 188 results found since Jan 2013.
Cost Effectiveness of the First ‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
ConclusionsThis was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.
Source: PharmacoEconomics - September 8, 2022 Category: Health Management Source Type: research
Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis
CONCLUSION: Results indicate high clinical need and economic burden among patients with severe presentation of SCD. These findings not only highlight the need for improved therapeutic options to limit or prevent disease progression, but also starts to provide insight on lifetime costs of SCD that will be needed in the evaluation of emerging curative intent therapies.PMID:36222016 | DOI:10.1080/13696998.2022.2133824
Source: Journal of Medical Economics - October 12, 2022 Category: Health Management Authors: Meghan Gallagher Anjulika Chawla Brenna L Brady Sherif M Badawy Source Type: research
Costs of major complications in people with and without diabetes in Tasmania, Australia
ConclusionsDiabetes complications are costly, and the costs are higher in people with diabetes than without diabetes. Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.PMID:36375176 | DOI:10.1071/AH22180
Source: Australian Health Review - November 14, 2022 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose Burgess John Timothy Saunder Alex Kitsos Nadine Wiggins Andrew J Palmer Source Type: research
Cost-Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in German Severe Aortic Stenosis Patients at Low Surgical Mortality Risk
ConclusionsTAVI with SAPIEN 3 appears to be a clinically meaningful, cost-effective treatment option over SAVR for patients with severe symptomatic aortic stenosis and low risk for surgical mortality in Germany.Clinical Trial Registration Numberwww.clinicaltrials.gov identifier: NCT02675114.
Source: Advances in Therapy - January 9, 2023 Category: Drugs & Pharmacology Source Type: research
